Today's edition of the Saxo Morning Call features the SaxoStrats team discussing the continuing weakness of the US dollar as commodity prices recover ground and in the wake of key US equity indices hitting all-time highs Thursday.
Medium term
Trade view / 18 April 2016 at 13:45 GMT

#SaxoStrats: Eurofins Scientific seen with upside

Head of Equity Strategy / Saxo Bank
Instrument: EUFI:xpar
Price target:
Market price:
Saxo Strats banner

Since 2013, Paris-listed Eurofins Scientific (EUFI:xpar) has taken market share and shown robust revenue and EBITDA growth. Capex will slow down over coming years, accelerating cashflow generation, and this could lead to higher multiples.

Eurofins Scientific share price performance

Source: Bloomberg, Saxo Bank

Eurofins is  trading at 12-month forward P/E ratio of 26.9, compared with 18.5 for global commercial services companies. Compared with its three publicly listed competitors (SGS, Intertek and Veritas), Eurofins also trades at a premium (around 20%), but that is warranted given its market share gains and leading position. Nevertheless, in view of the outlook for revenue growth, valuation multiples could expand further.

Eurofins valuation

Source: Bloomberg, Saxo Bank

Eurofions table

Management and risk description

Buy Eurofins Scientific (EUFI:xpar) at market with a trailing stop.

Key risks: stronger EUR against USD, with around 33% of revenue coming from  North America; increased competition, especially pharma/biotech, which is a very lucrative market, higher-than-expected capex needs.


Entry: Buy the stock at market with a trailing stop

Trailing stop:  €293.50 (volatility based), with step size of €3

Target: €400

Time horizon: Medium term

— Edited by John Acher

Non-independent investment research disclaimer applies. Read more


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail